Young patients sits at the center of this dementia and brain health question.
Young patients battling brain disorders are fighting a dual crisis: their neurological conditions and the insurance companies denying them treatment. Insurance claims for essential brain disorder treatments—particularly IVIG (intravenous immunoglobulin) for PANS/PANDAS, a rare inflammatory neuropsychiatric disorder—are increasingly rejected, with one recent appeals platform reporting success rate drops from 80% to just 60% since late 2024. A 12-year-old with sudden-onset obsessive-compulsive behavior and tics might be prescribed IVIG, a proven treatment costing over $9,000 per infusion, only to have the insurer deny the claim. This article examines why denials are climbing, how PANS/PANDAS patients are uniquely affected, what legal tools exist to fight back, and what families can actually do to access the treatments their children need.
The numbers are stark. Initial claim denials hit 11.8% in 2024, up from 10.2% the year before—with Medicare Advantage plans seeing a 4.8% jump. Among ACA marketplace plans, one in five claims were still denied as recently as 2026, though that represents a slight improvement from 22.5% in 2023. Seventy-seven percent of denials stem not from medical judgment, but from paperwork mistakes or plan design restrictions. The burden falls heaviest on young patients whose conditions are rare or whose treatments fall outside traditional insurance coverage assumptions.
Table of Contents
- Why Young Patients Face Rising Insurance Denials for Brain Disorder Treatments
- PANS/PANDAS—The Inflammatory Brain Disorder Young Patients Must Fight For
- The Cost and Access Crisis for IVIG and Other Essential Neurological Treatments
- New Tools and Resources: The Claimable Platform and Appeals Strategies
- Legal Battles and the Class Action Landscape
- FDA Approvals and Expanding Treatment Options for Young Patients
- The Policy Headwinds: Federal Enforcement Rollback and What It Means for Young Patients
- Conclusion
- Frequently Asked Questions
Why Young Patients Face Rising Insurance Denials for Brain Disorder Treatments
Denial rates have accelerated across the board, but young patients with neurological and neuropsychiatric conditions face particular barriers. Commercial health plans increased denial rates by 1.5 percentage points between recent years, while Medicare Advantage jumped 4.8%—a much steeper climb. The problem is compounded by which insurers dominate the market: Oscar Health denies 25.3% of claims, Molina Healthcare denies 22%, while Kaiser Permanente maintains a lower in-network denial rate around 6%. If a family’s employer selects a high-denial insurer, or if a young person is assigned to a worse-performing plan through the marketplace, the odds of fighting a claim are stacked against them from enrollment.
The stated reasons for denial are often procedural, not clinical. Insurers cite “lack of medical necessity documentation,” “authorization not obtained,” or “treatment not listed as covered”—complaints that can often be remedied with an appeal, yet many families never reach that stage. However, the appeal path itself carries risk: families may give up after the first denial, not realizing that the majority of denials are rooted in plan design or paperwork gaps, not medical judgment. Documentation requirements vary wildly by insurer, and what one plan considers “sufficient evidence” another will reject.
PANS/PANDAS—The Inflammatory Brain Disorder Young Patients Must Fight For
PANS (Pediatric Acute-onset Neuropsychiatric Syndrome) and PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infection) are rapid-onset neuropsychiatric conditions triggered by infection or immune dysfunction, affecting children and adolescents. A child with PANS might experience overnight-appearing severe OCD, tics, anxiety, mood swings, and cognitive decline—a cluster of symptoms that looks psychiatric but has an immunological root cause. Because these conditions are still relatively rare and still not universally recognized in pediatric neurology, insurance companies frequently deny coverage for their primary evidence-based treatment: IVIG. IVIG is a blood-derived immunotherapy that costs over $9,000 per infusion, with many patients requiring multiple infusions over months or years. Some children need six or more infusions as part of a complete treatment course, pushing total out-of-pocket costs into six figures even with partial insurance coverage.
The frustration for families is compounded by the fact that IVIG is mandated as covered treatment in only 12 states—meaning a family whose child has PANS faces an insurance denial in most of the country. Eight states have no mandate, and twelve have partial or limited mandates, leaving families in many areas to fight each denial individually. However, the situation has become more contentious since November 2024, when the American Academy of Pediatrics released a clinical report on PANS/PANDAS that insurers have weaponized to deny claims. The Claimable platform, a free AI-powered appeals service specifically designed to help PANS/PANDAS patients, has documented declining appeal success rates since the AAP report’s release, falling from approximately 80% to 60%. Meanwhile, seven additional peer-reviewed studies demonstrate IVIG benefits in neuropsychiatric outcomes and immune markers, and animal models show abnormal behavior reversed after IVIG—evidence that exists but is being overshadowed by selective interpretation of the AAP guidance.
The Cost and Access Crisis for IVIG and Other Essential Neurological Treatments
IVIG treatment represents both a medical breakthrough and a financial cliff. A single infusion costs over $9,000—a price that reflects the complexity of manufacturing immunoglobulin from donated human plasma and the regulatory oversight required. For a child diagnosed with PANS, an initial course typically involves six infusions over a 6-to-12-week period, totaling over $54,000 before insurance.
Even families with good coverage often face high deductibles, copays for specialty infusions, and the real risk that the entire claim will be denied upfront, forcing them to appeal. This creates a perverse incentive structure: families must either pay out-of-pocket while fighting the insurer through appeal, go without treatment, or relocate to one of the 12 states where IVIG is mandated for PANS/PANDAS. Some families have chosen all three—paying upfront, appealing simultaneously, and connecting with advocacy networks in states with stronger mandates. However, this calculus is impossible for many families. A household without $10,000 to $15,000 in savings cannot afford even the first infusion while an appeal is processed, effectively barring them from treatment regardless of medical necessity.
New Tools and Resources: The Claimable Platform and Appeals Strategies
In November 2024, Claimable launched a free, AI-powered appeals platform specifically designed to help children with PANS/PANDAS overcome insurance denials and secure IVIG treatment access. The platform automates the evidence collection and appeals letter generation process, allowing families to submit stronger, more comprehensive appeals without hiring expensive healthcare attorneys. For many families, Claimable has been the difference between securing treatment and giving up—the tool eliminated the need to navigate complex medical literature and insurance policy language on their own.
However, success rates have declined from approximately 80% to 60% since the platform’s November 2024 launch, a deterioration directly attributable to insurers’ increasing reliance on the 2024 AAP Clinical Report as justification for denials. The comparison is instructive: appeals built on established peer-reviewed evidence now compete against institutional guidance that, while cautious about IVIG’s routine use, has been selectively cited to deny even appropriate cases. Families using Claimable still see better success rates than those filing appeals without structured support, but the trend is troubling—the insurance industry is learning to defend denials more effectively, requiring appeals to become more sophisticated and labor-intensive.
Legal Battles and the Class Action Landscape
The courts have begun to hold insurers accountable for wrongful denials, though litigation is slow and requires significant resources. Anthem Inc. settled a class action lawsuit for $12.88 million over Mental Health Parity and Addiction Equity Act (MHPAEA) violations, a landmark case covering individuals denied residential treatment claims for behavioral health disorders. The settlement affirmed a fundamental principle: insurers cannot apply stricter standards to mental and neuropsychiatric conditions than they apply to medical conditions. Yet the battle continues case by case.
A key precedent is Wit v. United Behavioral Health (2020), in which a federal court ruled that United Behavioral Health illegally denied coverage for mental and substance use disorders based on flawed medical necessity criteria. The court found that UBH’s criteria were so restrictive that they made coverage virtually impossible to obtain, in violation of federal law. This case established that even when an insurer’s criteria appear neutral on their face, they can constitute illegal discrimination if their practical effect is to deny coverage for protected conditions. However, winning such a lawsuit requires resources few families possess, and the case-by-case approach means that each family with PANS/PANDAS must often fight alone, even when the legal principle is well-established.
FDA Approvals and Expanding Treatment Options for Young Patients
The FDA has been expanding treatment options for adolescents with neurological and neuropsychiatric conditions. NeuroStar, a transcranial magnetic stimulation device, was cleared by the FDA in 2024 as an adjunct treatment for major depressive disorder in adolescents aged 15-21, and multiple additional devices for adolescent MDD were cleared throughout 2025. These approvals matter because FDA clearance signals medical legitimacy—yet even FDA-cleared devices sometimes face insurance denials if they fall outside the insurer’s coverage policies.
The broader point is that therapeutic options exist and are expanding, but insurance access lags medical innovation. A 15-year-old approved for NeuroStar therapy might still find their insurer requires prior authorization, limits the number of sessions, or requires failed medication trials first—restrictions that have no scientific basis but persist because insurance plan design was written years before the technology existed. The same applies to IVIG for PANS/PANDAS and other emerging treatments: medical evidence advances, but insurance coverage rules do not automatically keep pace.
The Policy Headwinds: Federal Enforcement Rollback and What It Means for Young Patients
On May 12, 2025, the U.S. administration announced it would not enforce Biden-era mental health parity regulations that had strengthened requirements for equivalent mental and physical health coverage under the Mental Health Parity and Addiction Equity Act. This policy shift removes a critical enforcement mechanism that had been used to challenge discriminatory insurance practices.
Without active federal enforcement, insurers have less incentive to align their coverage policies for mental health and neuropsychiatric conditions with their medical coverage policies. This creates a critical juncture: the legal tools that had begun to hold insurers accountable for parity violations are weakening at the exact moment when denials for conditions like PANS/PANDAS are rising. Families and advocates will need to pursue claims through state regulators, private litigation, and the appeals process itself—each of which is slower and more resource-intensive than federal enforcement. The outlook for the next 2-3 years is uncertain: will insurers tighten coverage further, or will grassroots advocacy and patient networks maintain enough pressure to prevent deeper restrictions?.
Conclusion
Young patients with brain disorders—particularly conditions like PANS/PANDAS that require expensive, evidence-based treatments like IVIG—are fighting a system stacked against them. Insurance denial rates are climbing, specific insurers deny one in four claims, and only 12 states mandate coverage for IVIG treatment. The tools do exist: appeal platforms like Claimable, legal precedents like Wit v. UBH, and settlements like Anthem’s MHPAEA violation case.
However, these tools are insufficient without strong advocacy and medical documentation. If your child has been denied coverage for a neurological treatment, document everything, gather peer-reviewed evidence, file an appeal (preferably with support from platforms like Claimable), and consider connecting with advocacy networks like the PANS/PANDAS Network. Understand that 77% of denials stem from paperwork or plan design, not medical judgment—meaning many denials can be overturned with persistence and proper documentation. The fight is real, but it is winnable.
Frequently Asked Questions
What percentage of insurance claims for brain disorder treatments are denied?
Initial claim denials reached 11.8% in 2024, up from 10.2% previously. Among ACA marketplace plans, about one in five claims were denied as of 2026, though this represents improvement from 22.5% in 2023. Denial rates vary widely by insurer: Oscar Health denies 25.3%, Molina Healthcare 22%, while Kaiser Permanente denies around 6%.
Why are IVIG denials for PANS/PANDAS becoming more common?
Insurers have increasingly cited the 2024 American Academy of Pediatrics Clinical Report as justification for denials, even though seven additional peer-reviewed studies demonstrate IVIG benefits. Appeal success rates for IVIG treatment have declined from approximately 80% to 60% since November 2024, directly tied to this policy shift.
How much does IVIG treatment cost, and is it covered by insurance?
A single IVIG infusion costs over $9,000, with most treatment courses requiring multiple infusions. IVIG is mandated as covered treatment in only 12 states, leaving families in most of the country to fight for coverage through appeals and denials.
What should I do if my child’s insurance denies coverage for a neurological treatment?
File an appeal with comprehensive medical documentation. Consider using free appeal platforms like Claimable if your child has PANS/PANDAS. Gather peer-reviewed evidence supporting the treatment, and connect with advocacy networks like the PANS/PANDAS Network for support and additional resources.
Are there any recent legal wins against insurers for wrongful denials?
Yes. Anthem Inc. settled a class action for $12.88 million over Mental Health Parity violations, and a federal court in Wit v. United Behavioral Health (2020) ruled that insurers cannot apply unlawfully restrictive medical necessity criteria. However, enforcement has weakened since May 2025 with the rollback of federal parity enforcement.
What new treatment options are available for adolescents with neuropsychiatric conditions?
NeuroStar, a transcranial magnetic stimulation device, was FDA-cleared in 2024 for adolescents aged 15-21 with major depressive disorder, with additional devices cleared in 2025. However, even FDA-cleared treatments can face insurance denials based on plan design restrictions.
You Might Also Like
- Scientists Receive Support to Develop Novel Brain Disorder Treatment Methods
- The Hidden Costs of Declining Brain Function on Personal Independence
- Sedentary Screen Habits Linked to Higher Brain Deterioration Risk Levels
For more, see Alzheimer’s Association — caregiving.
